Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most prevalent complications of obesity. MASH is already the most common chronic liver disease, and is predicted to soon be the leading cause for liver transplant worldwide. Understanding mechanisms underlying MASH initiation and progression is likely to lead to novel and sorely needed therapy for a significant at-risk patient population. The proposed meeting will address several key knowledge gaps, including: •Does hepatocyte lipid accumulation affect cell-autonomous metabolic and regenerative processes? •What hepatocyte and systemic pathways determine liver inflammation and fibrosis? •Are there novel approaches to study MASH in vitro or in animal models? •Can we monitor MASH in patients using non-invasive biomarkers and imaging tools? We anticipate that attendees of this meeting will be exposed to the most current science in MASH pathogenesis, which in turn may lead to new academic collaborations with potential translational impact. Industry colleagues will in turn inform current and planned therapeutic approaches. This crosstalk will certainly lead to new insights into actionable mechanisms in MASH and may lead to novel therapies. Another distinguishing feature of the proposed meeting is the convergence of interdisciplinary expertise from bioengineering, metal biology and metabolism, which when coupled to talks from expert liver-focused clinicians, is likely to result in new in silico, in vitro and in vivo approaches to model MASH with eventual goal for novel treatment strategies.